Based on technique developed by the Principal Investigator that allows the muscularis mucosae (the innermost muscle layer of the intestine) from different anatomical locations to be studied in a uniform manner it has been shown that this muscle is not homogeneous. It exhibits clearly defined differences in its innervation and pharmacologic behavior along the length of the gut and in corresponding intestinal regions in different species. The proposed project utilizes three species, the North American opossum, the rabbit and the rat, to investigate potential mechanisms that may explain these observation.
Specific aim 1 is to characterize the nature of the neurotransmitters released by the nerves of the submucosal plexus innervating the muscularis mucosae in different intestinal regions. This is to test the hypothesis that disparate responses of different muscularis mucosae preparations are a function of their respective intrinsic innervation. This will be studied by the established in vitro technique of electrical field stimulation, in association with the use of selective pharmacologic agents that mimic or block the observed responses via receptor occupation or inhibition of transmitter synthesis or release.
Specific aim 2 is to comprehensively classify the receptor subtypes that mediate muscularis mucosae responses to the endogenous substances identified in specific aim 1. This is designed to test the hypothesis that differences in the pharmacologic behavior of the muscularis mucosae from different anatomical locations or species are a function of the receptor subtypes that the muscle possesses. This will be determined through the use of selective agonists and antagonists and the derivation of values such as the pA2 and the dissociation constant.
Specific aim 3 is to determine which second messengers are utilized by the muscle cells of the muscularis mucosae once endogenous compounds have interacted with the receptors identified in specific aim 2. This is to test the hypothesis that stimulation of the same receptor subtype in different preparations elicits contrasting effects because the receptor is not coupled to the same intracellular second messenger system. This will be achieved by quantitating agonist-evoked responses of the muscularis mucosae in terms of their respective phasic and tonic components and reevaluating these parameters following exposure to agents that selectively block different intracellular signal transduction pathways. These studies will, for the first time, allow region- and species-dependent differences in the characteristics of the muscularis mucosae to be quantitatively explained.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Academic Research Enhancement Awards (AREA) (R15)
Project #
1R15DK049805-01
Application #
2150726
Study Section
Toxicology Subcommittee 2 (TOX)
Program Officer
Hamilton, Frank A
Project Start
1995-06-01
Project End
1999-05-31
Budget Start
1995-06-01
Budget End
1999-05-31
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Connecticut
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Storrs-Mansfield
State
CT
Country
United States
Zip Code
06269
Wang, Q S; Guda, K; Papanikolaou, A et al. (2000) Expression of transforming growth factor beta1 and its type II receptor in mouse colon tumors induced by azoxymethane. Int J Oncol 17:551-8
Papanikolaou, A; Wang, Q S; Papanikolaou, D et al. (2000) Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 21:1567-72
Wang, Q S; Papanikolaou, A; Nambiar, P R et al. (2000) Differential expression of p16(INK4a) in azoxymethane-induced mouse colon tumorigenesis. Mol Carcinog 28:139-47
Papanikolaou, A; Wang, Q S; Mulherkar, R et al. (2000) Expression analysis of the group IIA secretory phospholipase A(2) in mice with differential susceptibility to azoxymethane-induced colon tumorigenesis. Carcinogenesis 21:133-8
Bolt, A B; Papanikolaou, A; Delker, D A et al. (2000) Azoxymethane induces KI-ras activation in the tumor resistant AKR/J mouse colon. Mol Carcinog 27:210-8
Wang, Q S; Walsh, A; Goldsby, J S et al. (1999) Preliminary analysis of azoxymethane-induced colon tumorigenesis in mouse aggregation chimeras. Carcinogenesis 20:691-7
Delker, D A; Wang, Q S; Papanikolaou, A et al. (1999) Quantitative assessment of azoxymethane-induced aberrant crypt foci in inbred mice. Exp Mol Pathol 65:141-9
Wang, Q S; Papanikolaou, A; Sabourin, C L et al. (1998) Altered expression of cyclin D1 and cyclin-dependent kinase 4 in azoxymethane-induced mouse colon tumorigenesis. Carcinogenesis 19:2001-6
Papanikolaou, A; Shank, R C; Delker, D A et al. (1998) Initial levels of azoxymethane-induced DNA methyl adducts are not predictive of tumor susceptibility in inbred mice. Toxicol Appl Pharmacol 150:196-203
Papanikolaou, A; Wang, Q S; Delker, D A et al. (1998) Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett 130:29-34

Showing the most recent 10 out of 11 publications